Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®

Date : 07/22/2019 @ 12:05PM
Source : PR Newswire (US)
Stock : Biocept Inc (BIOC)
Quote : 0.5132  -0.0738 (-12.57%) @ 5:00AM
After Hours
Last Trade
Last $ 0.55 ▲ 0.03 (6.20%)

Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®

Biocept (NASDAQ:BIOC)
Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more Biocept Charts.

SAN DIEGO, July 22, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into a Laboratory Services Provider Agreement with Beacon Laboratory Benefit Solutions, Inc. (BeaconLBS®), a nationally recognized premier provider of laboratory benefit management technology solutions to health and managed care companies in the United States. BeaconLBS administers laboratory benefit management programs for health plans to improve test ordering efficiency, test appropriateness, affordability, and quality of care for health plan members. To better serve the needs of physicians and patients, BeaconLBS connects them to its Labs-of-Choice™, which are preferred, high-quality laboratories, now including Biocept.

Biocept Logo (PRNewsFoto/Biocept, Inc.)

"We are very pleased to become a laboratory services provider for BeaconLBS, which offers innovative laboratory management technology solutions that benefit physicians, patients and payers," said Michael Nall, Biocept's President and Chief Executive Officer. "As a BeaconLBS Lab-of-Choice, more patients will have an opportunity to benefit from our liquid biopsy testing platforms, which can help physicians identify actionable biomarkers in patients diagnosed with cancer and design personalized treatment programs in order to improve outcomes."

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the expansion in the number of patients that will have an opportunity to benefit from our liquid biopsy testing platforms, our ability to improve the outcomes of patients diagnosed with cancer, and the potential clinical utility of our proprietary technology platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-laboratory-services-provider-agreement-with-beaconlbs-300888259.html

SOURCE Biocept, Inc.

Copyright 2019 PR Newswire

Latest BIOC Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.